Keywords
dipeptydyl peptidase-4 inhibitors
glucagon-like peptide 1
addiction
morphine
zebrafish
Abstract
Drug addiction is a chronic, recurrent disease of the central nervous system that leads to the development of comorbidities and premature death. Despite extensive scientific research concerning addiction, no effective method of addiction pharmacotherapy has been known so far. Glucagon-like peptide 1 has been suggested to play a role in the rewarding effect of addictive drugs. Linagliptin is a selective dipeptidyl peptidase-4 inhibitor that suppresses the rapid degradation of endogenous glucagon-like peptide-1. In clinical practice, it is used as an antidiabetic drug, but recent studies have confirmed its role in the activity of the central nervous system. This pilot study was conducted to ascertain whether linagliptin might influence morphine dependence – a locomotor activity test was carried out to assess the intensity of morphine withdrawal symptom. The obtained results clearly confirmed that linagliptin (0.01 and 0.1 mM) reduced the locomotor activity in morphine-dependent larval zebrafish. The undertaken experiments clearly indicates that linagliptin is involved in the addictive effects of morphine, thus, further studies on higher organisms should be carried out.References
1. Spanagel R, Almeida OF, Shippenberg TS. Long lasting changes in morphine-induced mesolimbic dopamine release after chronic morphine exposure. Synapse. 1993;14(3):243-5.
2. Koob GF, Ahmed SH, Boutrel B, Chen SA, Kenny PJ, Markou A, et al. Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev. 2004;27(8):739-49.
3. Motahari AA, Sahraei H, Meftahi GH. Role of nitric oxide on dopamine release and morphine-dependency. Basic Clin Neurosci. 2016;7(4):283-90.
4. Mocelin R, Marcon M, da Rosa Araujo AS, Herrmann AP, Piato A. Withdrawal effects following repeated ethanol exposure are prevented by N-acetylcysteine in zebrafish. Prog Neuropsychopharmacol Biol Psychiatry. 2019;93:161-70.
5. López-Patiño MA, Yu L, Cabral H, Zhdanova IV. Anxiogenic effects of cocaine withdrawal in zebrafish. Physiol Behav. 2008; 93(1-2): 160-71.
6. Novak U, Wilks A, Buell G, McEwen S. Identical mRNA for preproglucagon in pancreas and gut. Eur J Biochem. 1987;164(3): 553-8.
7. Donnelly D. The structure and function of the glucagon-like peptide-1 receptor and its ligands. Br J Pharmacol. 2012;166(1):27-41.
8. Lovshin JA, Drucker DJ. Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5:262-9.
9. Baggio LL, Yusta B, Mulvihill EE, Cao X, Streutker CJ, Butany J, et al. GLP-1 Receptor expression within the human heart. Endocrinology. 2018;159(4):1570-84.
10. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48(5):736-43.
11. Lankat-Buttgereit B, Goke R, Fehmann HC, Richter G, Goke B. Molecular cloning of a cDNA encoding for the GLP-1 receptor expressed in rat lung. Exp Clin Endocrinol. 1994;102:341-7.
12. Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett. 1995;358(3):219-24.
13. Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue, exendin-4, attenuates the rewarding properties of psychostimulant drugs in mice. PLoS One. 2013;8(7):e69010.
14. Sørensen G, Reddy IA, Weikop P, Graham DL, Stanwood GD, Wortwein G, et al. The glucagon-like peptide 1 (GLP-1) receptor agonist exendin-4 reduces cocaine self-administration in mice. Physiol Behav. 2015;149:262-8.
15. Egecioglu E, Engel JA, Jerlhag E. The glucagon-like peptide 1 analogue Exendin-4 attenuates the nicotine-induced locomotor stimulation, accumbal dopamine release, conditioned place preference as well as the expression of locomotor sensitization in mice. PLoS One. 2013b;8(10):e77284.
16. Tuesta LM, Chen Z, Duncan A, Fowler CD, Ishikawa M, Lee BR, et al. GLP-1 acts on habenular avoidance circuits to control nicotine intake. Nat Neurosci. 2017;20(5):708-16.
17. Shirazi RH, Dickson SL, Skibicka KP. Gut peptide GLP-1 and its analogue, Exendin-4, decrease alcohol intake and reward. PLoS One. 2013;8(4):e61965.
18. Sørensen, G, Caine SB, Thomsen M. Effects of the GLP-1 agonist Exendin-4 on intravenous ethanol self-administration in mice. Alcohol Clin Exp Res. 2016;40(10):2247-52.
19. Alhadeff AL, Rupprecht LE, Hayes MR. GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake. Endocrinology. 2012;153(2):647-58.
20. Oren DA, Wei Y, Skrabanek L, Chow BK, Mommsen T, Mojsov S. Structural mapping and functional characterization of zebrafish class B G-Protein Coupled Receptor (GPCR) with dual ligand selectivity towards GLP-1 and glucagon. PLoS One. 2016;11(12):e0167718.
21. Topkara B, Yananli HR, Sakallı E, Demirkapu MJ. Effects of injection of gamma-aminobutyric acid agonists into the nucleus accumbens on naloxone-induced morphine withdrawal. Pharmacology. 2017; 100(3-4):131-8.
22. Cachat J, Canavello P, Elegante M, Bartels B, Hart P, Bergner C, et al. Modeling withdrawal syndrome in zebrafish. Behav Brain Res. 2010; 208(2):371-6.
23. Khor BS, Jamil MF, Adenan MI, Shu-Chien AC. Mitragynine attenuates withdrawal syndrome in morphine-withdrawn zebrafish. PLoS One. 2011;6(12):e28340.
24. Bao W, Volgin AD, Alpyshov ET, Friend AJ, Strekalova TV, de Abreu MS, et al. Opioid neurobiology, neurogenetics and neuropharmacology in zebrafish. Neurosci. 2019;404:218-32.
25. Ninkovic J, Bally-Cuif L. The zebrafish as a model system for assessing the reinforcing properties of drugs of abuse. Methods. 2006;39:262-74.
26. Bardo MT, Rowlett JK, Harris MJ. Conditioned place preference using opiate and stimulant drugs: a meta-analysis. Neurosci Biobehav Rev. 1995;19:39-51.
27. Bretaud S, Li Q, Lockwood BL, Kobayashi K, Lin E, Guo S. A choice behavior for morphine reveals experience-dependent drug preference and underlying neural substrates in developing larval zebrafish. Neurosci. 2007;146(3):1109-16.
28. Webb KJ, Norton WH, Trümbach D, Meijer AH, Ninkovic J, Topp S, Heck D, et al. Zebrafish reward mutants reveal novel transcripts mediating the behavioral effects of amphetamine. Genome Biol. 2009;10(7):R81.
29. Darland T, Dowling JE. Behavioral screening for cocaine sensitivity in mutagenized zebrafish. Proc Natl Acad Sci U S A. 2001;98:11691-6.
30. Braida D, Limonta V, Pegorini S, Zani A, Guerini-Rocco C, Gori E. Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacol. 2007;190:441-8.
31. Rink E, Wullimann MF. Development of the catecholaminergic system in the early zebrafish brain: an immunohistochemical study. Brain Res. 2002;137:89-100.
32. Bertelli PR, Mocelin R, Marcon M, Sachett A, Gomez R, Rosa AR, et al. Anti-stress effects of the glucagon-like peptide-1 receptor agonist liraglutide in zebrafish. Prog Neuropsychopharmacol Biol Psychiatry. 2021;111:110388.
33. Douton JE, Augusto C, Stoltzfus B, Carkaci-Salli N, Vrana KE, Grigson PS. Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats. Behav Pharmacol. 2021;32(4):265-77.
34. Zhang Y, Kahng MW, Elkind JA, Weir VR, Hernandez NS, Stein LM, et al. Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats. Neuropsychopharmacol. 2020;45(3):451-61.
35. Pierce-Messick Z, Pratt WE. Glucagon-like peptide-1 receptors modulate the binge-like feeding induced by -opioid receptor stimulation of the nucleus accumbens in the rat. Neuroreport. 2020;31(18):1283-8.
36. Merchenthaler I, Lane M, Shughrue P. Distribution of pre-pro-glucagon and glucagon-like peptide-1 receptor messenger RNAs in the rat central nervous system. J Comp Neurol. 1999;403(2):261-80.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2022 Authors